![]() |
|
|
Vol. 281, Issue 1, 589-596, 1997
Departments of
Pharmacology (J.L., T.J.C., A.P., F.P.) and
Physiology (R.M.L.), University of Arizona Health Sciences Center,
Tucson, Arizona
Antisense oligodeoxynucleotides (ODN) have been used to inhibit the
function of a number of structurally defined neurotransmitter receptors
in vivo by transiently disrupting their expression in the
CNS. However, issues concerning the cellular and molecular mechanisms
of these ODN often raise questions about the specificity of such
ODN-mediated "knock-down" of target proteins. This study sought to
extend our in vivo "knock-down" of the delta
opioid receptor (DOR) by targeting this receptor in the NG 108-15 cells with an antisense ODN for the DOR and by using a polyclonal antibody raised against this receptor to determine the efficiency and
selectivity of the antisense ODN in inhibiting expression of the DOR.
By fluorescence tagging the ODN and immunofluorescence labeling the
DOR, we monitored the uptake efficiency of the ODN and the DOR density
in individual cells that had been treated with the antisense ODN or
with a mismatch control. Quantitative fluorescence image analysis
showed that the uptake of ODN by NG 108-15 cells was time- and
concentration-dependent and that it was not uniform within a
population. Treatment with the antisense ODN elicited an inverse
correlation between DOR immunoreactivity and the ODN fluorescence in
individual cells. No correlation was found in cells treated with the
mismatch control. These findings suggest that the antisense
ODN-mediated "knock-down" of the DOR is governed by the sequence
specificity of the ODN and the efficiency of its uptake by the target
cells in a time- and concentration-dependent manner. These data provide
further evidence in support of the selectivity of antisense ODN
targeting and the utility of these molecules as an effective tool in
neuropharmacological studies.